We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
226
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$391K 0.02%
+4,255
New +$454K
CARM
227
DELISTED
Carisma Therapeutics
CARM
$387K 0.02%
60,699
+50,997
+526% +$705K
MTEM
228
DELISTED
Molecular Templates, Inc.
MTEM
$385K 0.02%
5,078
-2,611
-34% -$154K
INSM icon
229
CALL
Insmed
INSM
$23.2B
$375K 0.02%
296
-30
-9% -$394
LPCN icon
230
CALL
Lipocine
LPCN
$17.1M
$355K 0.02%
21
– –
OCGN icon
231
Ocugen
OCGN
$410M
$345K 0.02%
2,511
+550
+28% +$87.1K
AGPU
232
Axe Compute Inc
AGPU
$78M
$345K 0.02%
+27
New +$3.94M
PVLA
233
Palvella Therapeutics
PVLA
$1.98B
$333K 0.02%
2,188
+1,248
+133% +$176K
TXMD icon
234
CALL
TherapeuticsMD
TXMD
$23.8M
$327K 0.02%
10
-110
-92% -$37.5K
ZSAN
235
DELISTED
Zosano Pharma Corporation
ZSAN
$296K 0.01%
184
– –
BDSI
236
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$295K 0.01%
912
-888
-49% -$3.28K
IONS icon
237
Ionis Pharmaceuticals
IONS
$9.35B
$284K 0.01%
+7,002
New +$284K
PRTK
238
CALL
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$282K 0.01%
+186
New +$2.85K
CPXX
239
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$276K 0.01%
25,000
-312,462
-93% -$1.02M
PVCT
240
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$275K 0.01%
726,200
-1,129,819
-61% -$465K
CMRX
241
DELISTED
Chimerix, Inc.
CMRX
$274K 0.01%
+53,620
New +$350K
VRTX icon
242
PUT
Vertex Pharmaceuticals
VRTX
$121B
$262K 0.01%
+33
New +$2.98K
ABUS icon
243
CALL
Arbutus Biopharma
ABUS
$865M
$260K 0.01%
630
+279
+79% +$997
TXMD icon
244
PUT
TherapeuticsMD
TXMD
$23.8M
$259K 0.01%
8
– –
CLVS
245
DELISTED
Clovis Oncology, Inc.
CLVS
$256K 0.01%
13,326
-7,597
-36% -$161K
JUNO
246
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$255K 0.01%
+67
New +$2.33K
NSPH
247
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$243K 0.01%
308,147
+141,913
+85% +$103K
CLRB icon
248
Cellectar Biosciences
CLRB
$19.3M
$242K 0.01%
24
-5
-17% -$77.4K
HRTX icon
249
CALL
Heron Therapeutics
HRTX
$86.3M
$239K 0.01%
126
+22
+21% +$434
VYNT
250
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$231K 0.01%
542
+120
+28% +$44.9K
8 9
10
11 12

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.